Member exclusive

Zirabev, Mvasi May Not Be Used to Treat Eye Disease, CMS Says

Nov 08, 2021

Public Health & Safety

Drugs

Drug Shortages

Administrative Burden

CMS has told Medicare Advantage plans that the two biosimilars, which are not clinically proven to treat eye disease and are potentially dangerous to ophthalmology patients, may not be used as substitutes for Avastin or be required in their step therapy programs.

Member exclusive

Log in to keep reading.

Join AAO to get unlimited access to content. See member benefits or join today.